LBIO Lion Biotechnologies Inc

Law Offices of Howard G. Smith Reminds Lion Biotechnologies, Inc. Investors of Pending Lawsuit And Upcoming Lead Plaintiff Deadline

Law Offices of Howard G. Smith reminds investors of the upcoming June 13, 2017 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of a class of investors who purchased or otherwise acquired Lion Biotechnologies, Inc. (“Lion” or the “Company”) (NASDAQ: LBIO) securities between November 14, 2013 and April 10, 2017, inclusive (the “Class Period”). Lion investors have until June 13, 2017 to file a lead plaintiff motion.

On April 10, 2017, the U.S. Securities and Exchange Commission found that between “September 2013 to March 2014, Lion, through its former Chief Executive Officer, Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions.” On this news, the price of Lion shares declined, thereby injuring investors.

According to the Complaint, during the Class Period, Lion made false and/or misleading statements and/or failed to disclose: (1) that the Company, through its former Chief Executive Officer, Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions; (2) that Singh engaged a notorious stock promotion firm to pay writers to publish articles about the Company on investment websites and to coordinate the distribution of articles to thousands of electronic mailboxes; (3) that Singh actively participated in the promotional work for Lion and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and (4) that as a result of the above, Lion's public statements were materially false and misleading at all relevant times.

If you purchased Lion securities, you may move the Court no later than June 13, 2017 to request appointment as lead plaintiff in the putative class action lawsuit. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action lawsuit. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to this lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
26/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lion Biotechnologies Inc

 PRESS RELEASE

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data ...

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) 26% Objective Response Rate  Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients...

 PRESS RELEASE

Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results a...

Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 SAN CARLOS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter 2025 financial results and corporate updates before market on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss these res...

 PRESS RELEASE

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 62,790 shares of Iovance’s common stock to nine new, non-executive...

 PRESS RELEASE

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 18, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 22,810 shares of Iovance’s common stock to two new, non-executi...

 PRESS RELEASE

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics to Present at Upcoming Conferences SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences: 2025 Wells Fargo Healthcare ConferenceFireside Chat: September 5, 2025 at 8:00 a.m. ETBoston, MA H.C. Wainwright 27th Annual Global Investment ConferencePresentation: September 9, 2025 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch